PLPL Entering Medical Marijuana Plandai

New Post Public Reply Private Reply Replies (0) Message Board

Nov 1, 2013 at 9:06 AM

*****PLPL Entering Medical Marijuana ***** Plandai Biotechnology, Inc. to Enter Medical Marijuana Field With Phyto Cannabinoid Extract Announces Formation of Cannabis Biosciences, Inc. to Develop Pharmaceutical Applications SEATTLE, WA--(Marketwired - Oct 30, 2013) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has formed a new wholly-owned subsidiary, Cannabis Biosciences, Inc., in Delaware, for the purpose of developing and testing a new Phytofare™ botanical extract derived from cannabis. Preliminarily dubbed Phytofare™ Phyto-cannabinoid Complex, the new extract will share a similar extraction process to the other Phytofare™ products and is expected to demonstrate the same high levels of bioavailability and purity. During the extraction process the company could also remove the psychoactive compound (THC), rendering a botanical drug that offers many of the medicinal benefits of cannabis without the perceived negative side effects and social stigma. Cannabis has shown strong medicinal potential across multiple fields in numerous independent clinical trials, including controlling symptoms of ALS (Lou Gehrig's Disease), Multiple Sclerosis and Crohn's disease, managing insulin levels in diabetics, and fighting breast cancer. THC has also been shown to help in reducing brain tumors and slowing the advance of Alzheimer's. In fact, the United States Department of Health and Human Services states in a 2001 U.S. Patent Application (Patent Number 6,630,507) that: "Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention." Roger Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, commented, "For the past twelve months, the Plandaí team has been working with cannabis to first ascertain if our patent-pending process could produce a phyto-cannabinoid extract that exhibits the same high bioavailability of our other Phytofare™ products. Working with cannabis presents unique challenges in that it produces a very sticky oil that must be dealt with -- and that only after navigating the complex legal obstacles. However, the medicinal opportunities associated with phyto-cannabinoids are simply too great to ignore." Mr. Duffield indicated that, having completed the science, preliminary bioavailability testing should commence in early 2014 with clinical trials commencing later in the year to pursue various pharmaceutical and nutraceutical applications. About Plandaí Biotechnology, Inc. Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com. Safe Harbor Statement The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws. Contact: Andrew Beyer Phone: 619-202-7456 Email: investor@Plandaíbiotech.com Disclaimer: http://alturl.com/3yt3r

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NEXCOM Fortifies Academic Networks with NGFW Platforms

Shielding Academic Networks in a Digital Era NEXCOM's stepping up to the plate to tackle the runaway train that is digital education. With classrooms going virtual and everything but the kitchen sink being plugged online, it's no wonder our beloved academic institutions are scrambling to hold the fort against cyber threats. Enter NEXCOM with their Next-Generation Firewall...

Sunlife Partners With Rippling to Streamline Benefits

Sunlife Enters the Tech Game It ain't your granddaddy's insurance world no more. Sunlife U.S. is hopping on the tech bandwagon, joining Rippling's Preferred Carrier Program to make employee benefits slicker and faster. This isn't just about insurance paperwork; it's about reshaping how businesses handle their payroll, IT, and HR under one digital roof. Why it Matters for...

RavenPack's Data Innovation: Sharpening Financial Analysis

Innovating Financial Analysis with AI They said AI would change everything, but who knew it'd make such a wave in turning research ideas into actionable datasets? RavenPack's latest maneuver is rewriting the playbook. By leveraging a fine-tuned NVIDIA Nemotron model, they've managed to label a mind-boggling 845,220 financial-text excerpts in under an hour. It's not just...

Fluence Energy Faces Massive Class Action Over Losses

Fluence Energy in Hot Water: Class Action Alert What a time to be catching the news on Fluence Energy, Inc. (NASDAQ: FLNC), a company that seemed like it was on the verge of taking the market by storm. But instead of riding high, they’re stuck in the mud, dealing with a securities class action lawsuit. This comes after a relentless punch to their market cap—about $3...

Hard Rock Casino Tejon Commences $725M Expansion Project

Ground Broken for Hard Rock Casino Tejon's Ambitious Expansion Who’s got a shovel ready? Hard Rock Casino Tejon does, kicking off a $725 million expansion that's turning heads all the way from Bakersfield to Los Angeles. Let's get something straight: this ain’t just another face-lift. We’re talking about a full-on transformation of the place into a plush resort...

ServiceTitan Faces Investigation: Stock Tanks 30%

ServiceTitan Lands in Hot Water Here we go again. News rolled in on September 8, 2026, catching investors like a deer in headlights. ServiceTitan, the operating systems provider that’s been riding the waves of the building and trades industries, just got clobbered with an investigation. As if grappling with their Max AI rollout wasn't enough, Robbins Geller Rudman &...

Compass Hit by Securities Fraud Suit; Investor Action Urged

Trouble Brewing for Compass Investors Amidst Legal Storm In the tangled web of mergers and acquisitions, Compass, Inc. (NYSE: COMP) finds itself in a legal quagmire that has investors on edge. The stark reality of a securities fraud class action lawsuit has emerged, centered around Compass’s January 2026 merger with Anywhere Real Estate Inc. The Heart of the Allegations...

CSL Names Deborah Waterhouse as CEO in Strategic Move

A Key Transition: Deborah Waterhouse Takes the Helm In a move that's sure to jolt the biopharma sphere, CSL Limited just handed the CEO reins over to Deborah Waterhouse. Set to start officially on February 1, 2027, this strategic appointment seems well plotted after a diligent global hunt by CSL's board for someone who can drive their enterprise into its next surge of...

deepset Strikes with AI Cost Solutions for Key Sectors

The AI Cost Conundrum: deepset's Strategic Leap deepset's latest move unleashes a fresh wind in the AI sector, tackling the financial drag from running high-caliber AI agents. With its Haystack Enterprise Platform, deepset isn't just coddling around the edges—it's going for the heart, where the budget bleeds most, and patching it up with a tech-savvy twist. Surfing the...

Sony's Game-Changing Sensor Reshapes Medical Endoscopy

In a world where medical tech innovation can make the difference between life and death, Sony’s latest feat will turn some heads in the healthcare industry. This ain’t about another PlayStation release; we’re talking the IMX742 CMOS image sensor crafted for single-use endoscopes. As far as breakthroughs go, the microscopic square sensor packs a surprising punch by...